Tykerb gets expanded US approval for breast cancer
01 February 2010
Malini Guha
GlaxoSmithKline's Tykerb (lapatinib) has been granted accelerated approval by the US
FDA to treat hormone positive and HER2-positive advanced breast cancer in postmenopausal women in combination with the hormonal therapy Femara (Novartis's letrozole).
This is the first time that Tykerb - an oral...
Please Login to read the full article.
01 February 2010
Malini Guha
This is the first time that Tykerb - an oral...
Please Login to read the full article.
RELATED CONTENT
NEWS
- NICE no for Tyverb and Herceptin in breast cancer, Roche considers appeal
- Tykerb and Herceptin work better together, study suggests
- Roche's T-DM1 (Herceptin-plus) shows early benefit in first-line metastatic breast cancer
- ImmunoGen to raise $84 million, adding own pipeline to Roche-licensed compounds
EVENTS
Today
London
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
